度洛西汀致抑郁症患者肝损伤。
Duloxetine-induced liver injury in patients with major depressive disorder.
机构信息
Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, Korea.
出版信息
Psychiatry Investig. 2011 Sep;8(3):269-71. doi: 10.4306/pi.2011.8.3.269. Epub 2011 Aug 10.
Abstract
Duloxetine is a balanced serotonin-norepinephrine reuptake inhibitor. Duloxetine-induced liver injury in patients with preexisting liver disease or chronic alcohol use is known. However, we have found that duloxetine can also induce liver injury in cases without those risk factors. We recommend that clinicians should monitor liver function carefully following duloxetine treatment.
摘要
度洛西汀是一种平衡的 5-羟色胺和去甲肾上腺素再摄取抑制剂。已知患有先前存在的肝脏疾病或慢性酒精使用的患者会发生度洛西汀引起的肝损伤。然而，我们已经发现，即使没有这些危险因素，度洛西汀也可能导致肝损伤。我们建议临床医生在使用度洛西汀治疗后应仔细监测肝功能。
相似文献
1
Duloxetine-induced liver injury in patients with major depressive disorder.度洛西汀致抑郁症患者肝损伤。
Psychiatry Investig. 2011 Sep;8(3):269-71. doi: 10.4306/pi.2011.8.3.269. Epub 2011 Aug 10.
2
Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder.度洛西汀致重症抑郁障碍患者胆汁淤积性黄疸
Psychiatry Investig. 2010 Sep;7(3):228-30. doi: 10.4306/pi.2010.7.3.228. Epub 2010 Aug 30.
3
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.艾司西酞普兰与度洛西汀治疗重度抑郁症急性期的双盲对照研究
Clin Drug Investig. 2007;27(7):481-92. doi: 10.2165/00044011-200727070-00005.
4
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.度洛西汀每日一次60毫克用于治疗重度抑郁症患者的疼痛性躯体症状。
J Psychiatr Res. 2005 Jan;39(1):43-53. doi: 10.1016/j.jpsychires.2004.04.011.
5
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.重度抑郁症患者突然停用度洛西汀治疗后的症状。
J Affect Disord. 2005 Dec;89(1-3):207-12. doi: 10.1016/j.jad.2005.09.003. Epub 2005 Nov 2.
6
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.度洛西汀治疗伴或不伴重度抑郁症的纤维肌痛女性的随机、双盲、安慰剂对照试验。
Pain. 2005 Dec 15;119(1-3):5-15. doi: 10.1016/j.pain.2005.06.031. Epub 2005 Nov 17.
7
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.度洛西汀（一种强效且平衡的5-羟色胺-去甲肾上腺素再摄取抑制剂）在大鼠持续性疼痛模型中的疗效。
J Pharmacol Exp Ther. 2004 Nov;311(2):576-84. doi: 10.1124/jpet.104.070656. Epub 2004 Jul 13.
8
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.一项双盲、多中心试验，比较度洛西汀与安慰剂治疗伴或不伴重度抑郁症的纤维肌痛患者的疗效。
Arthritis Rheum. 2004 Sep;50(9):2974-84. doi: 10.1002/art.20485.
9
Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.度洛西汀的给药模式和重度抑郁症患者开具高剂量处方的预测因素：来自美国第三方支付者视角的分析。
Clin Ther. 2011 Nov;33(11):1726-38. doi: 10.1016/j.clinthera.2011.09.027. Epub 2011 Oct 22.
10
Duloxetine for the management of fibromyalgia syndrome.度洛西汀治疗纤维肌痛综合征。
J Pain Res. 2009 Jul 21;2:99-108.
引用本文的文献
1
Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.酒精使用障碍的治疗：行为和药物治疗。
Clin Liver Dis. 2024 Nov;28(4):761-778. doi: 10.1016/j.cld.2024.06.011.
2
Alcohol Consumption Is a Coping Mechanism for Male Patients with Severe Anxiety Disorders Treated with Antidepressants Monotherapy.饮酒是接受抗抑郁药单药治疗的重度焦虑症男性患者的一种应对机制。
J Clin Med. 2024 May 6;13(9):2723. doi: 10.3390/jcm13092723.
3
Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials.化疗引起的周围神经病变的治疗：随机对照试验的系统评价
Front Pharmacol. 2022 Dec 23;13:1080888. doi: 10.3389/fphar.2022.1080888. eCollection 2022.
4
Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂度洛西汀在肝微粒体和小鼠中的代谢。
Drug Metab Dispos. 2022 Feb;50(2):128-139. doi: 10.1124/dmd.121.000633. Epub 2021 Nov 16.
5
Lorazepam as a Cause of Drug-Induced Liver Injury.劳拉西泮作为药物性肝损伤的一个病因
Case Rep Gastroenterol. 2018 Aug 31;12(2):546-550. doi: 10.1159/000492209. eCollection 2018 May-Aug.
6
Treatment of the depressed alcoholic patient.抑郁酒精依赖患者的治疗。
Curr Psychiatry Rep. 2012 Dec;14(6):610-8. doi: 10.1007/s11920-012-0314-7.
本文引用的文献
1
Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder.度洛西汀致重症抑郁障碍患者胆汁淤积性黄疸
Psychiatry Investig. 2010 Sep;7(3):228-30. doi: 10.4306/pi.2010.7.3.228. Epub 2010 Aug 30.
2
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.度洛西汀的肝脏效应-I：非临床和临床试验数据。
Curr Drug Saf. 2008 May;3(2):132-42. doi: 10.2174/157488608784529189.
3
The hepatic safety profile of duloxetine: a review.度洛西汀的肝脏安全性概况：综述
Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):281-5. doi: 10.1517/17425255.4.3.281.
4
Drug-induced liver injury: review article.药物性肝损伤：综述文章。
Dig Dis Sci. 2007 Oct;52(10):2463-71. doi: 10.1007/s10620-006-9472-y. Epub 2007 Mar 16.
5
Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.度洛西汀用于糖尿病性周围神经病理性疼痛患者：一项为期6个月的开放标签安全性研究。
Pain Med. 2006 Sep-Oct;7(5):373-85. doi: 10.1111/j.1526-4637.2006.00207.x.
6
Case report: fulminant hepatic failure involving duloxetine hydrochloride.病例报告：涉及盐酸度洛西汀的暴发性肝衰竭
Clin Gastroenterol Hepatol. 2006 Jul;4(7):912-7. doi: 10.1016/j.cgh.2006.04.018. Epub 2006 Jun 22.
7
Mechanisms of drug-induced liver injury.药物性肝损伤的机制。
AAPS J. 2006 Feb 3;8(1):E48-54. doi: 10.1208/aapsj080106.
8
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.度洛西汀治疗重度抑郁症的安全性和耐受性：八项安慰剂对照临床试验汇总数据的分析
Hum Psychopharmacol. 2005 Jul;20(5):327-41. doi: 10.1002/hup.696.
9
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.美国17家三级医疗中心对急性肝衰竭的前瞻性研究结果。
Ann Intern Med. 2002 Dec 17;137(12):947-54. doi: 10.7326/0003-4819-137-12-200212170-00007.
10
Safety of newly approved drugs: implications for prescribing.新批准药物的安全性：对处方开具的影响。
JAMA. 2002 May 1;287(17):2273-5. doi: 10.1001/jama.287.17.2273.
Zotero 插件